A Phase I Study of AK138D1 in the Treatment of Advanced Solid Tumors
- First Posted Date
- 2024-12-12
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Akeso
- Target Recruit Count
- 100
- Registration Number
- NCT06730386
- Locations
- 🇦🇺
Peninsula & South Eastern Haematology and Oncology Group, Frankston, Victoria, Australia
A Study to Evaluate the Efficacy and Safety of AK120 in Subjects With Moderate to Severe Atopic Dermatitis
- Conditions
- Interventions
- First Posted Date
- 2024-11-22
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Akeso
- Target Recruit Count
- 450
- Registration Number
- NCT06700499
- Locations
- 🇨🇳
Changde First People's Hospital, Changde, Hunan, China
🇨🇳XiangYa Hospital CentralSouth University, Changsha, Hunan, China
🇨🇳Yueyang Central Hospital, Yueyang, Hunan, China
AK137 (Bispecific Antibody Targeting CD73 and LAG-3) in Patients With Advanced Malignant Tumors
- First Posted Date
- 2024-11-15
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Akeso
- Target Recruit Count
- 87
- Registration Number
- NCT06691360
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, China
An Exploratory, Multi-cohort Phase II Study of Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-11-13
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Akeso
- Target Recruit Count
- 150
- Registration Number
- NCT06686030
AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-10-17
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Akeso
- Target Recruit Count
- 110
- Registration Number
- NCT06646055
A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Akeso
- Target Recruit Count
- 280
- Registration Number
- NCT06642792
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, China
A Study Evaluating the Single Subcutaneous Injection of Ebronucimab in Chinese Healthy Male Subjects
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Akeso
- Target Recruit Count
- 180
- Registration Number
- NCT06641388
- Locations
- 🇨🇳
The Third Xiangya Hospital of Central South University, Changsha, Hunan, China
A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC
- Conditions
- Interventions
- First Posted Date
- 2024-09-27
- Last Posted Date
- 2024-09-27
- Lead Sponsor
- Akeso
- Target Recruit Count
- 560
- Registration Number
- NCT06617416
- Locations
- 🇨🇳
Cancer Hospital of Shandong First Medical University, Jinan, China
A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
- Conditions
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Akeso
- Target Recruit Count
- 510
- Registration Number
- NCT06601335
- Locations
- 🇨🇳
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
🇨🇳West China Hospital of Sichuan University, Chengdu, Sichuan, China
AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-09-11
- Last Posted Date
- 2024-09-11
- Lead Sponsor
- Akeso
- Target Recruit Count
- 682
- Registration Number
- NCT06591520
- Locations
- 🇨🇳
Harbin Medical University Cancer Hospital, Harbin, China
🇨🇳Zhongshan Hospital, Fudan University, Shanghai, China